Advertisement
CPIX vs YCBD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPIX is a StrongBuy and YCBD is a Buy.
CPIX in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 26, 2026
CPIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 31 cases where CPIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CPIX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +3.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where CPIX advanced for three days, in 179 of 216 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 44 cases where CPIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CPIX as a result. In 100 of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CPIX turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In 47 of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
CPIX moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CPIX crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CPIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CPIX entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CPIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.738) is normal, around the industry mean (8.413). P/E Ratio (-5.959) is within average values for comparable stocks, (-1.728). CPIX's Projected Growth (PEG Ratio) (17.640) is very high in comparison to the industry average of (2.152). CPIX's Dividend Yield (1.379) is considerably higher than the industry average of (0.047). P/S Ratio (2.362) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CPIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
YCBD sees its Stochastic Oscillator climbs out of oversold territory
On October 20, 2026, the Stochastic Oscillator for YCBD moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 79 instances where the indicator left the oversold zone. In 72 of the 79 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where YCBD's RSI Indicator exited the oversold zone, 33 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for YCBD just turned positive on October 21, 2026. Looking at past instances where YCBD's MACD turned positive, the stock continued to rise in 38 of 38 cases over the following month. The odds of a continued upward trend are 90%.
YCBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on YCBD as a result. In 97 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YCBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for YCBD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.495) is normal, around the industry mean (9.012). P/E Ratio (1.577) is within average values for comparable stocks, (-3.044). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. YCBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YCBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
CPIX | YCBD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 68 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 34 | 88 | |
P/E GROWTH RATING 1..100 | 12 | 68 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
YCBD's Valuation (42) in the Other Consumer Services industry is in the same range as CPIX (52) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew similarly to CPIX’s over the last 12 months.
CPIX's Profit vs Risk Rating (68) in the Pharmaceuticals Other industry is in the same range as YCBD (100) in the Other Consumer Services industry. This means that CPIX’s stock grew similarly to YCBD’s over the last 12 months.
CPIX's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as YCBD (98) in the Other Consumer Services industry. This means that CPIX’s stock grew similarly to YCBD’s over the last 12 months.
CPIX's Price Growth Rating (34) in the Pharmaceuticals Other industry is somewhat better than the same rating for YCBD (88) in the Other Consumer Services industry. This means that CPIX’s stock grew somewhat faster than YCBD’s over the last 12 months.
CPIX's P/E Growth Rating (12) in the Pharmaceuticals Other industry is somewhat better than the same rating for YCBD (68) in the Other Consumer Services industry. This means that CPIX’s stock grew somewhat faster than YCBD’s over the last 12 months.
| CPIX | YCBD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 89% | 4 days ago 82% |
| Stochastic ODDS (%) | 1 day ago 86% | 4 days ago 90% |
| Momentum ODDS (%) | 1 day ago 90% | 4 days ago 90% |
| MACD ODDS (%) | 1 day ago 81% | 4 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 82% | 4 days ago 82% |
| TrendMonth ODDS (%) | 1 day ago 84% | 4 days ago 90% |
| Advances ODDS (%) | 4 days ago 83% | N/A |
| Declines ODDS (%) | 8 days ago 81% | 4 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 4 days ago 80% |
| Aroon ODDS (%) | 1 day ago 77% | 4 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CPIX’s FA Score shows that 1 FA rating(s) are green while YCBD’s FA Score has 0 green FA rating(s).
- CPIX’s FA Score: 1 green, 4 red.
- YCBD’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CPIX’s TA Score shows that 3 TA indicator(s) are bullish while YCBD’s TA Score has 5 bullish TA indicator(s).
- CPIX’s TA Score: 3 bullish, 7 bearish.
- YCBD’s TA Score: 5 bullish, 2 bearish.
Price Growth
CPIX (@Pharmaceuticals: Generic) experienced а -35.07% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was +4.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.57%. For the same industry, the average monthly price growth was -11.91%, and the average quarterly price growth was +7.55%.
Reported Earning Dates
CPIX is expected to report earnings on Nov 03, 2026.
YCBD is expected to report earnings on Dec 18, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-3.57% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
CPIX and
Correlation & Price change
A.I.dvisor tells us that CPIX and ACB have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CPIX and ACB's prices will move in lockstep.
| Ticker / NAME | Correlation To CPIX | 1D Price Change % | ||
|---|---|---|---|---|
| CPIX | 100% | -48.76% | ||
| ACB - CPIX | 27% Poorly correlated | +0.52% | ||
| QNTM - CPIX | 26% Poorly correlated | -1.34% | ||
| GLAS - CPIX | 23% Poorly correlated | N/A | ||
| YCBD - CPIX | 23% Poorly correlated | +0.61% | ||
| PRGO - CPIX | 22% Poorly correlated | -0.88% | ||
More | ||||
YCBD and
Correlation & Price change
A.I.dvisor indicates that over the last year, YCBD has been loosely correlated with TLRY. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if YCBD jumps, then TLRY could also see price increases.
| Ticker / NAME | Correlation To YCBD | 1D Price Change % | ||
|---|---|---|---|---|
| YCBD | 100% | -2.74% | ||
| TLRY - YCBD | 58% Loosely correlated | -4.10% | ||
| TRLV - YCBD | 48% Loosely correlated | -4.58% | ||
| GLAS - YCBD | 43% Loosely correlated | -6.14% | ||
| CRON - YCBD | 40% Loosely correlated | -2.76% | ||
| DERM - YCBD | 24% Poorly correlated | -1.38% | ||
More | ||||